Sponsored by
Unfortunately the trial did not meet it's endpoint of median overall survival. I did not really expect it to as the immunotherapies appear to help only a small subset of patients, but when they do - it helps a lot. This leads to a long tail of survivors, but the median does not change. All of the immunotherapies by themselves will probably have this same problem. I think the key is to combine them to the point where most people benefit. I wouldn't write this off until we see the complete results and see if there is a signficant tail.